Brachytherapy

Vivos Inc Implements Multiple Patient IsoPet® Therapy Day

Retrieved on: 
Thursday, April 21, 2022
Amputation, Gel, Confusion, University, Food and Drug Administration, FedEx, Marketing, Johns Hopkins University, Half-life, Food, Human, Private Securities Litigation Reform Act, Vivos, GLOBE, Sale, Patient, Engineering, Tissue, Neoplasm, FDA Center for Devices and Radiological Health, Structured Product Labeling, Technology, Temperature, Company, OTCQB, Method, Radiation, Forward-looking statement, Animal, Policy, Safety, Veterinary medicine, Hydrogel, Name, FDA, Washington State University Reactor, Brachytherapy, Sarcoma, Pharmaceutical industry, Medical imaging

The Isopet treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.

Key Points: 
  • The Isopet treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).
  • Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
  • Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet to University animal hospitals and private veterinary clinics.

Merit Medical Receives FDA Clearance for SCOUT Bx™ Delivery System

Retrieved on: 
Monday, April 11, 2022
Endoscopy, NASDAQ, BX, Leadership, Reading, Biopsy, Cardiology, Breast, Woman, Radar, Cancer, Radiology, Hospital, CEO, MMSI, MD, Critical care, Intermountain Healthcare, GLOBE, Physician, Brachytherapy, Trauma, MRI, FDA, Breast cancer, Patient, Medical imaging, Merit

SOUTH JORDAN, Utah, April 11, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, has received FDA clearance for the SCOUT Bx Delivery System, the first wire-free breast localization solution that can be deployed at the time of stereotactic or MRI-guided biopsy.

Key Points: 
  • SOUTH JORDAN, Utah, April 11, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, has received FDA clearance for the SCOUT Bx Delivery System, the first wire-free breast localization solution that can be deployed at the time of stereotactic or MRI-guided biopsy.
  • SCOUT Bx is compatible with the most commonly used stereotactic and MRI guided breast biopsy devices on the market, allowing the patient to avoid an additional procedure.
  • The SCOUT Bx system is designed to allow clinicians to offer this streamlined pathway to a broader group of patients.
  • The SCOUT Bx system is the newest addition to the Merit Oncology Breast and Soft Tissue Localization portfolio.

The Worldwide Brachytherapy Treatment Planning Systems Industry is Expected to Reach $1.5 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 28, 2022
Health, Other Health, Adoption, Brachytherapy, WHO, Investment, Machine learning, Diagnosis, Death, Colorectal cancer, News, Data mining, Cancer, Man, Renal & Urology News, Prevalence, Health, Artificial intelligence, Industry, Prostate cancer, Chapter Three, Breast cancer, AI, Lung cancer, Algorithm, Pharmaceutical industry, Medical device, Medical imaging

Some of the most commonly diagnosed cancer cases are breast cancer, prostate cancer, lung cancer, and colorectal cancer.

Key Points: 
  • Some of the most commonly diagnosed cancer cases are breast cancer, prostate cancer, lung cancer, and colorectal cancer.
  • The dramatically rising prevalence of cancer is boosting the demand for innovative cancer care therapies with precise and accurate outcomes.
  • The oncology care industry is witnessing a surge in innovations and investments by key participants developing novel technologies, which are anticipated to significantly transform the cancer care treatment regime.
  • Along with the growing prevalence of cancer, the rising number of radiotherapy centers with technologies for better brachytherapy treatment planning is boosting the market growth.

Promaxo Announces Sale of In-Office MRI to Arizona State Urological Institute

Retrieved on: 
Wednesday, March 16, 2022
Technology, GLOBE, Patient, Pleasure, Partnership, Hospital, FDA, Prostate, AI, Brachytherapy, Diagnosis, MRI, Sale, Company, Man, Woman, CEO, San Tan Valley, Arizona, Magnetic resonance imaging, Prostate cancer, ASUI, Robotics, Medical imaging

OAKLAND, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona State Urological Institute (ASUI).

Key Points: 
  • OAKLAND, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona State Urological Institute (ASUI).
  • Arizona State Urological Institute was founded in May 2003 and provides comprehensive urological care to the areas surrounding Phoenix, Arizona, with three offices in the East Valley (Gilbert, Chandler and Phoenix) and one office in the San Tan Valley.
  • Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform.
  • The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

Biobot Surgical signs MOU with BEBIG Medical to collaborate on a robotic-guided prostate brachytherapy solution

Retrieved on: 
Friday, March 11, 2022
Prostate, Automation, Infection, Partnership, MDR, Cancer, Prostate cancer, Needle, Health, Artificial intelligence, U.S. FDA, Radiation, Patient, Technology, Man, MOU, Brachytherapy, CEO, HDR, Medical device, Medical imaging, EU

Biobot Surgical developed the iSR'obot Mona Lisa 2.0, a robotic-assisted percutaneous surgical system that allows clinicians to plan and position needles during image-guided diagnostic and interventional prostate procedures.

Key Points: 
  • Biobot Surgical developed the iSR'obot Mona Lisa 2.0, a robotic-assisted percutaneous surgical system that allows clinicians to plan and position needles during image-guided diagnostic and interventional prostate procedures.
  • "BEBIG Medical is a well established brand in brachytherapy, while Biobot Surgical is known for its accurate placement of needles.
  • The partnership enables our companies to bring robotic-assisted brachytherapy solutions to patients," said Mr. Sim Kok Hwee, CEO of Biobot Surgical.
  • BEBIG Medical GmbH ("BEBIG Medical") is a global provider of high quality radiation therapy products for cancer treatment headquartered in Berlin, Germany.

Sensus Healthcare Sells Its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash

Retrieved on: 
Wednesday, March 2, 2022
Terminology, Dermatology, Innovation, SRT, Patient, Artificial intelligence, Research, Food and Drug Administration, Industry, Forward-looking statement, Food, Quality of life, Brachytherapy, Government, Keloid, Annual report, BOCA, Security (finance), U.S. Securities and Exchange Commission, Simnia sculptura, Ownership, Solution, Board, Sale, Cancer, COVID-19, Time, Radiation, Marketing, Tax, Beam, Risk, Intellectual property, Nasdaq, Legislation, GLOBE, Medical imaging, SensUs, Empyrean

BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura assets to Empyrean Medical Systems for $15 million in cash.

Key Points: 
  • BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura assets to Empyrean Medical Systems for $15 million in cash.
  • The sale, completed on Feb. 25, 2022, included inventory of Sculptura systems and parts, in addition to all related intellectual property.
  • "We are thrilled to acquire and add the Sculptura to Empyrean's arsenal of cancer-vanquishing products and solutions," said Kal Fishman, chairman, and chief executive officer of Empyrean Medical Systems.
  • Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.

Sensus Healthcare Sells its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash

Retrieved on: 
Wednesday, March 2, 2022
Terminology, Dermatology, Innovation, SRT, Patient, Artificial intelligence, Research, Food and Drug Administration, Industry, Forward-looking statement, Food, Quality of life, Brachytherapy, Keloid, Government, Annual report, BOCA, Security (finance), U.S. Securities and Exchange Commission, Simnia sculptura, Ownership, Solution, Sale, Cancer, COVID-19, Time, Radiation, Marketing, Tax, Beam, Risk, Intellectual property, Nasdaq, Legislation, GLOBE, Medical imaging, Risk management, SensUs, Empyrean

BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura™ assets to Empyrean Medical Systems for $15 million in cash.  The sale, completed on February 25, 2022, included inventory of Sculptura™ systems and parts, in addition to all related intellectual property.

Key Points: 
  • BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura assets to Empyrean Medical Systems for $15 million in cash.
  • The sale, completed on February 25, 2022, included inventory of Sculptura systems and parts, in addition to all related intellectual property.
  • We are thrilled to acquire and add the Sculptura to Empyreans arsenal of cancer-vanquishing products and solutions, said Kal Fishman, chairman and chief executive officer of Empyrean Medical Systems.
  • Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.

Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131

Retrieved on: 
Wednesday, March 2, 2022
Neck, Risk, Private Securities Litigation Reform Act, ISO, Toxicity, UIR, Literature, Patient, Research, Treatment, Twitter, Radio, Brachytherapy, University of Pittsburgh School of Medicine, News, University, LinkedIn, FDA, SEC, Company, Head, Wilfrid Sellars, Cancer, Compliance, FIR, Trial of the century, Prostate cancer, PSLRA, Hereditary nonpolyposis colorectal cancer, Lung, Isotope, Seed, Intellectual property, Physician, Prostate-specific antigen, PSA, Brain, GLOBE, Medical imaging, Medicine, IsoRay, Facebook, MD

The study analyzed the outcomes for 335 intermediate-risk prostate cancer patients treated with Cesium-131 brachytherapy.

Key Points: 
  • The study analyzed the outcomes for 335 intermediate-risk prostate cancer patients treated with Cesium-131 brachytherapy.
  • The study found both the favorable (147 patients) and unfavorable (188 patients) intermediate-risk groups demonstrated excellent biochemical outcomes.
  • For 135 favorable patients treated with Cesium-131 implant alone (excluding 12 patients who were treated with external beam radiation therapy and Cesium-131 implant), the outcome was 98.1%.
  • In localized prostate cancer, risk increases as PSA (prostate-specific antigen), tumor grade, and tumor stage advance, creating higher risk of treatment failure.

Vivos Inc. Enhances its Intellectual Property Protection

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Half-life, Human, Method, Washington State University Reactor, Neoplasm, Animal, Name, Brachytherapy, Food and Drug Administration, Hydrogel, University, Radiation, Tissue, Gel, Company, Sale, Private Securities Litigation Reform Act, Safety, Veterinary medicine, Temperature, Food, Structured Product Labeling, FDA, Sarcoma, OTCQB, Forward-looking statement, Marketing, Union, Patent, Vivos, Technology, Engineering, Confusion, FDA Center for Devices and Radiological Health, Medical imaging, Pharmaceutical industry

Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries.

Key Points: 
  • Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries.
  • In closing Dr. Korenko stated, Intellectual property protect is always a priority and over time becomes increasingly important.
  • Our strategic plan is to use our intellectual property as a foundation for our exclusive licensing strategy in several regions in the world.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).

RaySearch Laboratories : Year-end report 2021

Retrieved on: 
Wednesday, February 23, 2022
Proton, POS, Webcast, Genolier Swiss Medical Network SA, SEK, Brachytherapy, CFO, Operating cost, Proton therapy, Uncertainty, COVID-19, Karolinska Institute, OIS, TCS, OAS, RaySearch Laboratories, EU, IBA, TPS, FLASH, Nasdaq Stockholm, CEO, CET, Weapon, Pharmaceutical industry, Medical imaging, Flour

RaySearch secured a large order for RayStation from Lanzhou Ion Therapy, a Chinese manufacturer of accelerator systems.

Key Points: 
  • RaySearch secured a large order for RayStation from Lanzhou Ion Therapy, a Chinese manufacturer of accelerator systems.
  • RaySearch and Mevion Medical Systems have expanded their collaboration on the development of advanced treatment planning techniques for FLASH delivery with the Mevion S250i Proton Therapy System.
  • New CFO of RaySearch took over on November 15, 2021.
  • RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment.